VEA
RYTM icon

Virtus ETF Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

Virtus ETF Advisers’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,280
Closed -$352K – 731
2024
Q4 		$352K Sell
6,280
-1,143
-15% -$63.1K 0.14% 198
2024
Q3 		$389K Hold
7,423
– – 0.18% 206
2024
Q2 		$305K Sell
7,423
-1,451
-16% -$57.9K 0.15% 227
2024
Q1 		$385K Buy
8,874
+1,277
+17% +$55.9K 0.2% 200
2023
Q4 		$349K Sell
7,597
-9,596
-56% -$303K 0.22% 187
2023
Q3 		$394K Sell
17,193
-2,221
-11% -$49.7K 0.24% 180
2023
Q2 		$320K Buy
19,414
+9,010
+87% +$163K 0.19% 186
2023
Q1 		$186K Buy
10,404
+183
+2% +$4.6K 0.1% 312
2022
Q4 		$298K Buy
+10,221
New +$263K 0.16% 269
2022
Q2 		– Sell
-16,317
Closed -$188K – 469
2022
Q1 		$188K Sell
16,317
-973
-6% -$8.54K 0.08% 201
2021
Q4 		$173K Buy
17,290
+7,061
+69% +$79.3K 0.07% 271
2021
Q3 		$134K Sell
10,229
-536
-5% -$8.19K 0.06% 360
2021
Q2 		$211K Buy
10,765
+826
+8% +$17.2K 0.09% 308
2021
Q1 		$211K Buy
9,939
+167
+2% +$4.84K 0.09% 320
2020
Q4 		$291K Sell
9,772
-5,612
-36% -$143K 0.12% 227
2020
Q3 		$333K Sell
15,384
-2,100
-12% -$48.1K 0.17% 201
2020
Q2 		$390K Buy
17,484
+2,260
+15% +$44K 0.18% 209
2020
Q1 		$232K Sell
15,224
-2,226
-13% -$39.9K 0.1% 264
2019
Q4 		$401K Buy
17,450
+6,142
+54% +$136K 0.07% 252
2019
Q3 		$244K Sell
11,308
-630
-5% -$13.5K 0.05% 218
2019
Q2 		$263K Buy
11,938
+2,470
+26% +$62.4K 0.06% 264
2019
Q1 		$260K Sell
9,468
-1,044
-10% -$30K 0.55% 75
2018
Q4 		$283K Sell
10,512
-3,532
-25% -$97.6K 0.05% 132
2018
Q3 		$410K Sell
14,044
-10,330
-42% -$326K 0.04% 158
2018
Q2 		$762K Buy
+24,374
New +$666K 0.67% 62

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus ETF Advisers's RYTM Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2025, closing a stake of 6,280 shares — an estimated $352K sold.

Virtus ETF Advisers first reported a position in RYTM in Q2 2018 and held it in 25 quarters. The position peaked at $762K in Q2 2018. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Rhythm Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,280 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $352K.
  • Virtus ETF Advisers first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 25 quarters.
  • Virtus ETF Advisers's Rhythm Pharmaceuticals position peaked at $762K in Q2 2018.
  • 228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.